Nuveen’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-104,738
| Closed | -$3.51M | – | 3838 |
|
|
2026
Q1 | $3.51M | Buy |
104,738
+4,116
| +4% | +$161K | ﹤0.01% | 2045 |
|
|
2025
Q4 | $4.66M | Buy |
100,622
+5,997
| +6% | +$329K | ﹤0.01% | 1939 |
|
|
2025
Q3 | $6.4M | Sell |
94,625
-109,242
| -54% | -$8.1M | ﹤0.01% | 1790 |
|
|
2025
Q2 | $17.1M | Buy |
203,867
+119,037
| +140% | +$8.91M | ﹤0.01% | 1202 |
|
|
2025
Q1 | $6.06M | Buy |
84,830
+21,725
| +34% | +$1.06M | ﹤0.01% | 1823 |
|
|
2024
Q4 | $2.84M | Buy |
63,105
+3,627
| +6% | +$188K | ﹤0.01% | 2238 |
|
|
2024
Q3 | $3M | Hold |
59,478
| – | – | ﹤0.01% | 2227 |
|
|
2024
Q2 | $2.43M | Buy |
+59,478
| New | +$2.52M | ﹤0.01% | 2288 |
|
|
2021
Q2 | – | Sell |
-10,055
| Closed | -$191K | – | 3516 |
|
|
2021
Q1 | $191K | Sell |
10,055
-1,718
| -15% | -$55.4K | ﹤0.01% | 3244 |
|
|
2020
Q4 | $341K | Buy |
11,773
+3,300
| +39% | +$95.2K | ﹤0.01% | 3115 |
|
|
2020
Q3 | $319K | Buy |
8,473
+1,801
| +27% | +$52.6K | ﹤0.01% | 3072 |
|
|
2020
Q2 | $223K | Buy |
+6,672
| New | +$289K | ﹤0.01% | 3084 |
|
Nuveen's SLNO Position: Q2 2026 in Review
Nuveen sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 104,738 shares — an estimated $3.51M sold.
Nuveen first reported a position in SLNO in Q2 2020 and held it in 12 quarters. The position peaked at $17.1M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Nuveen reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Nuveen sold 104,738 Soleno Therapeutics shares in Q2 2026, an estimated $3.51M.
- Nuveen first reported a position in Soleno Therapeutics in Q2 2020 and held it in 12 quarters.
- Nuveen's Soleno Therapeutics position peaked at $17.1M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.